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Role of necroptosis in the pathogenesis of solid
organ injury
H Zhao1, T Jaffer1, S Eguchi1, Z Wang1, A Linkermann2 and D Ma*,1
Necroptosis is a type of regulated cell death dependent on the activity of receptor-interacting serine/threonine-protein (RIP)
kinases. However, unlike apoptosis, it is caspase independent. Increasing evidence has implicated necroptosis in the
pathogenesis of disease, including ischemic injury, neurodegeneration, viral infection and many others. Key players of the
necroptosis signalling pathway are now widely recognized as therapeutic targets. Necrostatins may be developed as potent
inhibitors of necroptosis, targeting the activity of RIPK1. Necrostatin-1, the first generation of necrostatins, has been shown to
confer potent protective effects in different animal models. This review will summarize novel insights into the involvement of
necroptosis in specific injury of different organs, and the therapeutic platform that it provides for treatment.
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Facts
 Necroptosis is a type of regulated cell death dependent on
the activity of receptor-interacting serine/threonine-protein
(RIP) kinases
 Necroptosis induces inflammation through the release
of Danger-associated molecular patterns (DAMPs), such
as HMGB-1.
 Necroptosis is closely associated with acute injury in brain,
heart, lung, kidney, liver, intestine and pancreas.
Open Questions
 What is the exact molecular mechanism of necroptosis in
solid organ injury?
 How is necroptosis related to diagnosis and prognosis of
the solid organ injury?
 Which therapeutic strategy would be the most effective
against necroptosis-associated solid organ injury in clinical
settings?
Apoptosis and necrosis are two pathologically relevant
types of cell death. Apoptosis is programmed cell death
controlled tightly during development and in physiological
cellular turnover; necrosis, which also occurs in trauma, was
thought to occur predominantly in an uncontrolled manner.1
Necroptosis involves the loss of membrane integrity, release of
damage-associated molecular pattern molecules (DAMPs)
and is therefore closely associated with inflammatory
response.2 It involves the activation of specific death
mediators such as receptor-interacting protein (RIP) kinases
and mixed-lineage kinase domain-like protein (MLKL).3,4
Recent studies implicate that necroptosis is of central
relevance in different disease states, such as myocardial
infarction,5 stroke6 and organ graft ischemia–reperfusion
injury (IRI).7–9 This review will summarize new insights into
the molecular mechanisms of necroptosis in different patho-
logical conditions and provide an overview of the currently
available therapeutic approaches, which target necroptosis in
organ injury.
Molecular Mechanism of Necroptosis
The molecular pathway of tumor necrosis factor alpha (TNF-α)-
induced necroptosis is the mostly intensively investigated
(Figure 1). TNF-α-induced necroptosis involves two
members of the receptor-interacting protein (RIP) family of
kinases – RIPK1 and RIPK3.3,10 Tumor necrosis factor-α
(TNF-α) can bind to one of two receptors, TNFR1 or TNFR2.
TNFR activation can cause the activation of NF-κB which
leads to the induction of proinflammatory cytokines.11 How-
ever, the activation of TNFR1 may turn into a death signal,
which recruits several proteins.12 Upon TNF stimulation,
TNFR1 complex I is formed at the plasma membrane,
containing cellular inhibitor of apoptosis protein 1 (cIAP-1)
and transforming growth factor-β-activated kinase 1 (TAK1).13
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The transition from TNFR1 complex I to the cytosolic death-
inducing TNFR1 complex II requires the activity of cylindroma-
tosis (CYLD), a deubiquitylating enzyme.14 More recent
data15,16 suggest that CYLD likely regulates activation of RIPK1
in Complex II, rather than transition from Complex I to Complex
II. Within TNFR1 complex II, the apoptotic machinery FADD,
c-FLIP and caspase-8 suppresses the induction of necroptosis.
Caspase-8 inactivates RIPK1 and RIPK3 by proteolytic
cleavage and the proapoptotic caspase activation is
initiated.12 Mechanistic data indicate that CYLD is essential for
necrosis and serve as a target for proteolysis by caspase-8.17
When caspase-8 is inactivated or absent, RIPK1 andRIPK3 are
not cleaved and become phosphorylated.1 They then form a
necrosome18 and the cell undergoes necroptosis.12 RIPK1 then
recruits RIPK3 through RIP (RHIM) domain mediated-
interactions. This RIPK1–RIPK3 interaction promotes the
recruitment and phosphorylation of mixed-lineage kinase
domain-like (MLKL) protein.18,19 Phosphorylated MLKL forms
tetramers and translocates onto the plasmamembrane,4,19 and
in turn initiates Ca2+ influx.19 In addition, RIPK3 is reported to
activate a number of different downstream signals such as
phosphoglycerate mutase 5 and finally dynamin-related protein
(Drp1) to induce reactive oxygen species (ROS) production in
the mitochondria.14 The RIPK3-multimers are stabilized by
chaperones that are essential for necroptosis.20
It is currently unclear which molecular switch mechanism
controls the decision of whether apoptosis or necroptosis is
executed, but first reports from TAK1-deficient cells suggest a
critical importance of this kinase and its co-factors.21 Lamothe
et al.22 reported that TNF-α-induced cell death was abrogated
by the inhibition of caspases and knockdown of RIPK3 in
TAK1-deficient mouse embryonic fibroblasts, indicating that
TAK1 is an important modulator of both apoptosis and
necroptosis. Saveljeva et al.23 demonstrated that repression
Figure 1 Signalling pathways after stimulation of the TNFR1. TNF-α is widely released during inflammatory conditions. (a) Upon binding to TNF receptor 1, TNF receptor 1
recruit TRADD, TRAF2 and 5, RIP-1, cIAPs and other molecules to form complex I. (b) Upon polyubiquitinated RIP-1, TNFR1-signalling activates NF-kB, leading to expression of
proinflammatory cytokines. The deubiquitination of RIPK1 by CYLD leads to the formation of complex II. (c) Caspase-8 activation in complex II prevents necroptosis through
preventing activation RIP, and suppresses the induction of necroptosis. (d) Inactivation of Caspase-8 in complex II leads to the phosphorylation and activation of RIPK1, RIPK3
and MLKL during the assembly of the necrosome. RIPK3 activates PGAM5 and Drp1 to induce reactive oxygen species (ROS) production in the mitochondria and mediate
plasma membrane rupture. Abbreviation: TNF, tumor necrosis factor; TRADD, TNFRSF1A-associated via death domain; TRAF, TNF receptor associated factors; cIAPs, cellular
inhibitor of apoptosis protein; CYLD, deubiquitinase cylindromatosis; MLKL, mediator mixed-lineage kinase domain like; RIP, receptor-interacting protein kinase; PGAM5,
phosphoglycerate mutase 5; Drp1, dynamin-related protein 1
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of TNFR1, RIPK1 or MLKL shifted endoplasmic reticulum
stress induced necroptosis to apoptosis. Necroptosis is
caspase independent and is not inhibited by caspase
inhibitors, such as zVAD fluoromethyl ketone.7 Necroptosis
can be inhibited by Necrostatin-1 through suppression of
RIPK1 activity.24 The difference between apoptosis, necrosis
and necroptosis is summarized in Table 1.
RIPK1 has been shown to be involved in RIPK3/MLKL-
dependent necroptotic cell death.25,26 However, RIPK1 was
found to drive NF-κB-mediated cell survival and inflamma-
tion through activating downstream of either TNFR1 or
TNFR227 as well as caspase-8-dependent apoptotic cell
death.26 Depletion of RIPK1 has been shown to lead to
enhanced sensitization to TNF-induced apoptosis26 and
pharmacological inhibition of RIPK1 activities is associated
with suppression of necroptosis.28 Recent data clearly
indicate that RIPK1 serves a critical kinase-independent
scaffolding role and prevents inappropriate activation of both
RIPK3-dependent necroptosis and caspase-8-dependent
apoptosis.25–27,29,30
Necroptosis and Inflammation
Necroptosis is considered to be proinflammatory31 (Figure 2).
Animal studies have revealed critical involvement for
necroptosis in the pathogenesis of inflammatory
diseases.32 Necroptosis is also demonstrated to lead to
the release of damage-associated molecular patterns
(DAMPs)32 (Table 2). DAMPs in the extracellular milieu
trigger activation of the immune system and initiate
inflammation. High-mobility group protein B1 (HMGB-1)
is a typical DAMP molecule that initiates inflammation
through toll-like receptors TLR-2 and TLR-4.33 Lau et al.9
demonstrated that RIPK1/RIPK3-mediated necroptosis
regulates HMGB-1 release and HMGB-1 was reduced in
RIPK3− /− renal graft after injury. Further in-depth studies
need to be carried out to identify DAMPs specific for
necroptosis, which would provide better interpretation of
the role of necroptosis in tissue inflammation and provide new
therapeutic targets for inflammatory diseases.34
Necroptosis in Organ Injury
Accumulating laboratory studies demonstrate that acute or
chronic organ injury can lead to necroptosis.35 To date,
necroptosis has been found to be present as a result of certain
disease or injury in major organs of the body (Figure 3).
Understanding of necroptosis in the pathophysiology of
various diseases may offer unique opportunities for clinical
management of such patients.
Brain
Neonatal hypoxia–ischemia brain injury: Necroptosis has
been recognized as an important mechanism of injury in
neonatal hypoxia–ischemia (HI) brain injury.36 In the mouse
model of neonatal HI,37 Necrostatin-1 blocked the interaction
of RIPK1 and RIPK3 in the neurons. Cytokine gene and
protein expression, such as interleukin IL-1β, IL-6 and TNFα
was suppressed, and NF-kB activation was inhibited. This
study showed that Necrostatin-1 could be protective against
neonatal brain injury after HI through attenuation of
necroptosis-associated neuro-inflammation.
Traumatic brain injury: Necroptosis has been shown to play a
critical role in the pathogenesis of cell death during traumatic
brain injury (TBI). Mice administered with Necrostatin-1 had
reduced brain damage and improved motor and cognitive
performance after TBI.6 Necrostatin-1 has been demon-
strated to decrease brain neutrophil infiltration and suppress
microglial activation.6 These data therefore suggest that
Necrostatin-1 may offer a new therapeutic perspective for
treatment of patients with TBI.
Ischemic stroke: The pathological relevance of necroptosis
in an ischemic stroke setting was established in a study by
Degterev et al.38 In a mouse model of transient focal cerebral
ischemia, it was shown that necroptosis contributed
to delayed ischemic brain injury. In addition, intracerebroven-
tricular administration of Necrostatin-1 markedly decreased
the infarct volume, indicating a therapeutic potential for
stroke.
Table 1 Difference between apoptosis, necrosis and necroptosis
Apoptosis Necrosis Necroptosis
Type of cell death Controlled Uncontrolled Controlled
Trigger Trauma, toxic stress, self-renew, aging,
development.
Trauma, toxic stress, infection Trauma, toxic stress, infection
Morphology Extensive membrane blebbing,
condensation and fragmentation of the
nucleus31
Extensive organelle and cell swelling,
loss of membrane integrity, release of
extracellular contents31
Cytoplasmic swelling, rupture of the
plasma membrane and spilling of the
intracellular content99
Signalling pathway Specific, intrinsic or extrinsic pathways Unspecific Specific, e.g TNFR1 pathway
Executioner Caspase, (caspase-3, -6, -7, -8 and -9) RIP kinase (RIPK1 and RIPK3)
Role of mitochondria Release of cytochrome c, interaction
with Bcl-2 protein family. Mitochondrial
dysfunction
Mitochondrial dysfunction, collapse of
mitochondrial membrane potential
Failure of ATP production
Mitochondrial dysfunction, Production
of ROS.
AIF release
Complex formed Apoptosome Necroptosome
Inflammatory response Anti- or proinflammatory response Pro-inflammatory response Pro-inflammatory response
DAMP release Yes100 Yes Yes
Inhibitor Z-VAD fmk Necrostatin-1
Human condition Physiological or pathological condition Pathological condition Pathological condition
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Hemorrhagic stroke: Although the role of necroptotic cell
death after hemorrhagic stroke remains unexplored,39 the
potential protective effect of Necrostatin-1 on such stroke has
been investigated recently. In a mouse model of intracerebral
hemorrhage,40 administration of Necrostatin-1 significantly
reduced hematoma volume, neuronal cell death, reactive
astrogliosis and neurovascular injury. The neurological
outcomes were significantly improved after Necrostatin-1
treatment.
Amyotrophic lateral sclerosis: A study by Re et al.41 found
that necroptosis is the key mechanism of neurodegeneration
in both sporadic and familial types of amyotrophic lateral
sclerosis (ALS). The sporadic and familial ALS astrocytes
caused neuronal death by necroptosis in a RIPK1-dependent
manner. Necrostatin-1 abrogated the mouse motor neuron
loss in ALS.
Neurodegenerative disease: Necroptosis has been impli-
cated in mediating neuronal excitotoxicity, which is asso-
ciated with chronic neurodegeneration such as in
Alzheimer’s and Parkinson’s diseases.24 Treatment with
Necrostatin-1 protects against glutamate-induced oxytosis
in hippocampal HT-22 cells.42 Furthermore, NMDA-induced
excitotoxicity has been shown to be lowered in the
rat cortical neurons through using Necrostatin-1.43 The
molecule 24(S)-hydroxycholesterol (24S-OHC) was found to
induce neuronal cell death via necroptosis in a neuro-
blastoma cell line.44 24S-OHC is usually found as a
cholesterol eliminator in brains, with increased levels in those
patients with Alzheimer’s disease.45 Treatment of cells with
Necrostatin-1 significantly suppressed cell death induced by
24S-OHC. This indicated that high levels of 24S-OHC might
Figure 2 Necroptosis and inflammatory response. Necroptosis has been shown to commonly occur in the acute organ injury, especially in the organ transplantation. For
example, during renal graft ischemia–reperfusion injury, (a) renal tubular epithelial cells undergoing necroptosis release DAMP molecules such as high-mobility group box 1
protein (HMGB-1), which is recognized by receptors, such as receptor for advanced glycation end products (RAGE) and Toll-like receptors 2, 4 and 9 (TLR-2, -4 and -9), reactive
oxygen species (ROS) and inflammatory cytokines, such as TNF-α, leading to immune cell activation. (b) Inflammatory cells produce and release proinflammatory chemokine
(e.g. CXCL1, CXCL2) and cytokines (e.g. IL-1 and -6) and promote tissue inflammation, infiltration of monocyte and neutrophils. (c) Infiltrating monocytes produce ROS and
inflammatory cytokines such as TNF-α enhance the necroptosis in the epithelial cells. (d) Epithelial cells undergoing necroptosis could lead to the release and presentation of
donor antigens by dendritic cells and activation of the acquired immune system, such as T cells and B cells. The immune rejection is then initiated. (e) Brown-Norway rat kidney
was extracted and stored in UW solution for 24 h, and then transplanted into the Lewis recipient. Histology study demonstrated typical pathological progression possibly due to
necroptosis. (1) Renal tubular cells. (2) Necrotic cells by ischemia–reperfusion injury 24 h after transplantation and (3) enhanced cellular infiltration during acute immune rejection
4 days after transplantation. The level of injury is gradually increased
Table 2 A list of DAMP molecules possibly associated with necrotic or/and
necroptotic cells
Ligand Receptor
HMGB-1 RAGE, TLR-2, -4 and -9101,102
Histone TLR-2 and -4103,104
ATP P2X, P2Y105
HSP CD24106,107
DNA TLR-9108
ECM components, e.g. fibronectin,
fibrinogen, hyaluronan and biglycan
TLRs, CD44107,109
IL-33 ST2L/IL1RAcP34,110
Cyclophilin A CD147111,112
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lead to necroptosis of neurons and contribute to the
development of neurodegenerative diseases.46,47
Lung
Lung infection: The cIAP may play a role in necroptosis
within the lung during pulmonary infection.48 A study of
necroptosis of macrophages demonstrated that with deficient
cIAP-1, the mice had a greater Chlamydophila pneumoniae
viral load, as well as a reduced number of macrophages.48
A deficiency in cIAP-1 would increase the risk of necroptosis
due to increased formation of necrosomes. Flu infections
caused necroptosis in the lung and bronchiole epithelial
tissue,49 mediated by RIPK1 and RIPK3, and inhibiting either
or both of these proteins in mice has shown to be effective
against lung infection.48 Recently, the role of necroptosis in
listeria infection has been pointed out in detail.50
Remote lung injury: Several reports have independently
demonstrated that necroptotis is involved in remote lung
injury. A recent study by Zang et al.51 examined rat lungs that
were affected by acute kidney injury (AKI), and found that the
lung cells with remote injury were undergoing both apoptosis
and necroptosis. Furthermore, necroptosis was reported to
be involved in remote lung injury after kidney graft IRI.52 In a
rat renal allogeneic transplantation model, the expression of
RIPK1 was enhanced in lung alveolar epithelial cells due to
renal graft IRI, possibly due to enhanced local and systemic
TNF-α.52 Blocking necroptosis through Necrostatin-1 con-
ferred protection against remote lung injury after receiving
ischemic renal allografts.52
Chronic obstructive pulmonary disease: Necroptosis was
described to be involved in chronic obstructive pulmonary
disease.53 In a study conducted by Mizumura et al.,53
cigarette smoke induced mitochondrial dysfunction in epithe-
lial cells, and lung epithelial cells displayed increased
expression of RIPK3. These findings implicated that necrop-
tosis occurs in lung emphysematous changes in response to
cigarette smoke exposure. The role of mitochondria in
necroptosis has been discussed in more detail by Tait
et al.,54 and they demonstrated that necroptosis is executed
independently of mitochondrial permeability transition.
Transfusion-induced lung injury: Red blood cell transfusion
had been shown to promote lung inflammation and induced
necroptosis of lung endothelial cells.55 Necroptosis and the
subsequent release of inflammatory mediators is a novel
mechanism of injury following transfusion that may account
for the increased risk of acute respiratory distress syndrome
in such patients.55
Kidney
Cisplatin-induced kidney injury: Necroptosis may be asso-
ciated with the cisplatin toxicity-associated cell death56 and
Necrostatin-1 has been shown to confer protection in
cisplatin-treated human proximal tubular cells.57 In the mouse
model of cisplatin-induced AKI, the deterioration of renal
morphology was attenuated by Necrostatin-1.20 However,
there are possible explanations, which include non-
necroptotic functions of RIPK3 and off-target effects of
Necrostatin-1 that might explain these findings which are
not ruled out in detail. Renal tubular cells as such, when
depleted from caspase-8 or FADD, are not sensitive to
necroptosis in the cisplatin model.58
Renal ischemia–reperfusion injury: Recent work has further
implicated the relevance of necroptosis in AKI, especially
renal IRI.59 It has been demonstrated that Necrostatin-1
protects from renal IRI, a finding that suggests that RIPK1-
dependent necroptosis is present and has functional rele-
vance in the pathophysiological course of ischemic kidney
injury.28 Importantly, this study indicated the absence of an
apoptotic contribution to deterioration of acute ischemic
kidney failure. To rule out potential off-target effects of
Necrostatin-1 and non-necroptotic functions of RIPK3, the
potential inhibition of RIPK1-mediated necroptosis by
Necrostatin-1s, a stable and highly RIPK1 kinase specific
compound, remains to be investigated. Preliminary studies
do not indicate a protective effect of Necrostatin-1s in this
very same model. The investigation of RIPK1-kd (kinase
dead) knock-in mice is currently expected to clarify this issue.
Renal transplantation: RIPK3-mediated necroptosis was
demonstrated to be present in renal transplantation and has
a major impact on kidney transplant survival.9 TNF-α is
expressed by infiltrating cells as well as kidney parenchymal
cells during AKI, which enhanced RIPK3 expression.
Figure 3 Necroptosis and organ injury. Necroptosis has been identified in various
organs, including heart, lung, liver, kidney, gastrointestinal tract and central
nervous system
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Enhanced survival was observed in RIPK3− /− kidney graft
recipients. Studies to investigate Necrostatin-1s and
Necrostatin-1 in a transplant setting are urgently awaited,
but are delayed due to the short half-life of these small
molecules. Importantly, for the transplant situation in parti-
cular, the side effects upon immunosuppression, especially
viral control, should be carefully looked at.
Heart
Cardiac ischemia and infarction: It was reported60 that
necrostatins inhibited myocardial cell death and reduced
infarct size in the isolated perfused heart. In a study
performed on guinea pig hearts, Koshinuma et al.61 looked
at the effect of inhibition of necroptotic and apoptotic cell
death on protection against ischemia injury. The combined
treatment of necroptosis inhibitor Necrostatin-1 and apopto-
sis inhibitor zVAD led to reduced infarct size and a greater
involvement of the RIPK1-mediated necroptosis pathway was
demonstrated.61 In addition, RIPK3-deficient mice were
strongly protected in a model of myocardial infarction.5 In a
mouse model of cardiac IRI,62 Necrostatin-1 administration
reduced infarct size, inhibited RIPK1/RIPK3 phosphorylation,
and significantly reduced cell death. Therefore, Necrostatin-1
as a compound and RIPK3 as a therapeutic target currently
attract tremendous interest in this pathway from pharmaceu-
tical companies.
Cardiac transplantation: RIPK1 and RIPK3 were reported to
contribute to cardiac allograft survival through necroptotic
death.8 Necroptotic cell death and release of the danger
molecule HMGB-1 were suppressed by Necrostatin-1
and by genetic deletion of RIPK3. RIPK3 deficiency in heart
allografts led to less severe damage in the endothelium and
myocytes, and prolonged graft survival after transplantation.
Atherosclerosis: RIPK3-dependent necroptosis in mouse
models of atherosclerosis has been intensively
investigated.63 It has been shown that RIPK3 has limited
involvement in the early development of atherosclerosis,
but has a promoting effect on advanced atherosclerosis.
RIPK3 deficiency reduced inflammation and macrophage
infiltration in advanced atherosclerotic lesions.
Gastrointestinal tract
Crohn’s and ulcerative colitis: RIPK1 was reported to
regulate homeostasis and suppress inflammation in barrier
tissues by inhibiting epithelial cell apoptosis and
necroptosis.64 A study into children with inflammatory bowel
disease showed that necroptosis might contribute to its
progression by heightening intestinal inflammation.65 The
study, by Pierdomenico et al., found a statistically significant
result in children with two main bowel diseases – namely
Crohn’s and ulcerative colitis. RIPK3 levels increased while
caspase-8 decreased, which was a strong indicator for the
presence of necroptosis. It is currently very suggestive to
think of necroptosis as a cause of chronic inflammation in the
gut, which might be dependent of RIPK3 and MLKL,
potentially explaining the outstanding therapeutic success
of infliximab, a drug that directly interferes with TNF-α.66,67
Terminal ileitis: Gunther et al.68 demonstrate necroptosis in
the terminal ileum of patients with Crohn's disease and
suggest that regulating necroptosis in the intestinal epithe-
lium is critical for the maintenance of intestinal immune
homeostasis. Deletion of caspase-8 from intestinal epithelial
cells led to spontaneous necroptosis, causing a Crohn’s-like
phenotype in mice.68 Paneth cells appear to be critically
involved in this process. Mice with a conditional deletion of
caspase-8 in the intestinal epithelium treated with
Necrostatin-1 had a much higher survival rate than those
that did not receive the treatment.
Liver
Alcoholic steatohepatitis: The exact role of necroptosis in
alcoholic steatohepatitis remains unclear. Roychowdhury
et al.69 reported that ethanol feeding activates both apoptotic
as well as non-apoptotic cell death pathways. Ethanol
induced RIPK3 expression that was independent of presence
or absence of caspase inhibitor. Chronic ethanol-fed mice
showed increased RIPK3 expression. Moreover, the liver
biopsies of alcoholic liver disease patients also showed
increased RIPK3 expression, which indicates the execution
of necroptosis in human hepatic pathologies.69
Non-alcoholic steatohepatitis: Gautheron et al.70 used the
methionine- and choline-deficient diet-induced model of
steatohepatitis as a model of non-alcoholic steatohepatitis.
RIPK3 mediates liver injury, inflammation, induction of
hepatic progenitor cells/activated cholangiocytes and liver
fibrosis.70 RIPK3 thus represents a promising target for future
therapeutic strategies in patients with chronic metabolic liver
disease. It has been suggested that MLKL increases
mitochondrial ROS production and contributes to necroptosis
during hepatic injury.71
Hepatotoxicity: The role of Necrostatin-1 in protecting liver
cell damage was recently investigated in the model of
acetaminophen (APAP) induced hepatotoxicity.72,73 APAP
induced the phosphorylation of RIPK1 and hence necrosome
formation, and Necrostatin-1 was effective in blocking
necrosome formation during APAP-induced hepatotoxicity
via inhibition of RIPK1.72
Liver infection: Recent studies highlight the critical role of
necroptotsis in organ infection. Infection by Listeria mono-
cytogenes induced the early necroptotic death of Kupffer
cells, which caused monocyte recruitment and an antibacter-
ial type 1 inflammatory response.50 Kupffer cell necroptosis
triggered hepatocytes to release the alarmin interleukin-33
(IL-33) and enhanced basophil IL-4 production.74 Chronic
hepatitis C virus (HCV) infection results in progressive liver
fibrosis leading to cirrhosis and liver cancer. HCV promoted
cell death in primary and immortalized hepatocytes, and this
was inhibited by Necrostatin-1.75 These findings indicate that
HCV-induced cell death occurs through necroptosis, and
provides new insights into the mechanisms of HCV-induced
liver injury.75
Remote liver injury: Necroptosis was shown to be present in
remote hepatic injury associated with ischemic acute kidney
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injury (AKI).76 TNFR and RIPK3 showed significantly high
expression levels in immunoblot analyses, and positive
hepatocytes of RIPK3 immunohistochemical staining were
also evident in livers of rats with ischemic AKI.
Pancreas
Acute pancreatitis: RIPK3 deficiency was published by two
initial reports in which the role of RIPK3 was highlighted77,78
for partial protection from cerulein-induced pancreatitis (CIP),
suggesting that necrotizing pancreatitis may be attenuated by
pharmacological interference of this pathway.78,79 However,
other groups, who intended to reproduce this result, failed to
do so and in fact observed stronger organ damage in the
presence of Necrostatin-1.79 Recently, the same group also
described that RIPK3-deficient mice are not protected from
CIP.58 However, MLKL deficiency in a newly generated
knockout mice was again shown to be responsible for the
protection in the CIP model.80 In this regard, investigation of
positivity for pMLKL in human pancreatitis sections would be
very helpful to clarify the issue.
Hematopoietic system
Bone marrow failure: A study by Roderick et al.30 revealed
that hematopoietic RIPK1 deficiency triggered both apoptotic
and necroptotic death that was partially prevented by RIPK3
deficiency, but the role of TAK1 was not investigated here.
Therefore, the inhibitory function of RIPK1 on RIPK3-
mediated necroptosis regulated hematopoiesis and pre-
vented inflammation in this model. Interestingly, RIPK3− /−
bone-marrow-derived dendritic cells were highly defective in
lipopolysaccharide (LPS)-induced expression of inflamma-
tory cytokines.81 This dendritic cell -specific function of RIPK3
was critical for injury-induced inflammation and tissue
repair.81 Rickard et al.29 demonstrated an essential physio-
logical role for RIPK1 in immune homeostasis and emer-
gency hematopoiesis. RIPK1 could inhibit RIPK3/MLKL
necroptosis and RIPK3 and MLKL deficiency prevented
RIPK1− /− systemic inflammation. Specifically, bone marrow
failure described by Roderick et al.30 and Rickard et al.29
reflects the loss of normal tissue homeostasis associated
with the loss of RIPK1 protein and is different from the
inappropriate activation of RIPK1 kinase activity. Similarly, the
study by Moriwaki et al.81 demonstrated the kinase-
independent role of RIPK3 in inflammation, which is again
different from its kinase-dependent role in necroptosis.
Necroptosis as a Therapeutic Target
RIP-1 inhibitor. The central role of RIPK1 and RIPK3 in
initiating necroptosis led to the assumption that inhibiting RIP
is a good strategy against necroptosis.82,83 Necrostatins in
animal disease models have been proven to be very useful
experimental probes.84 However, RIPK1 kinase activity is not
only limited to necroptosis but is also involved in ERK13 and
NF-κB activation,85 therefore the biological effect after in vivo
RIP inhibitor administration should be carefully interpreted.86
The kinase domain of RIPK1 appears to be of central
importance in sepsis/LPS/TNF-mediated shock models.25,27
A range of chemical or biological compounds have been
proposed or investigated as potential inhibitors of RIPK1 in
organ injury.
Necrostatin-1: Recently, the 5-(1H-indol-3-ylmethyl)-2-thio-
hydantoin 1, termed Necrostatin-1 (or Nec-1), was reported
to inhibit necroptosis induced by TNF-α.82,87 Necrostatin-1
has been considered an effective agent of necroptosis
inhibition – possibly because the main cause of necroptosis
is RIPK1 and RIPK3 forming the necrosome. However, this
treatment so far has only been used in the preclinical stage,
so further studies are needed for its development as a drug
for clinical use. The precise function of the kinase-inhibitor
Necrostatin-1 is well established that this molecule is an
allosteric inhibitor of RIPK1, stabilizing a specific inactive
conformation of the kinase domain.82,88 It inhibits in vitro
necroptosis and the in vivo effects seen with this compound
are strong, and have been reported by several groups.
RIPK1/3 activation is induced by homotypic RHIM domain
interactions with upstream activators, such as TRIF.89 Loss
of RIPK1 leads to the new parameters of direct RIPK3
activation by the same adaptors, which is clearly detri-
mental to the organism. However, this also indicates that
the conclusion that necroptosis is RIPK1-independent has
to be considered very carefully as regulation of RIPK3 in the
presence of RIPK1 and its absence is not equivalent.
Instead, it is clear that Necrostain-1 lacks activity in the
absence of RIPK1, indicating its specific mode of action.
Rather, these data indicate that RIPK1 has an important
dual role in controlling cell death: both as an attenuator of
RIPK3 activation under normal circumstances and as an
inducer when necroptosis is activated under pathologic
conditions. Thus, activation of necroptosis in RIPK1− /−
cells is not always a clear reflection of the lack of RIPK1 role
under normal circumstances. In addition, RIPK1-kd knock-
in mice are viable whereas whole-body RIPK1-ko are lethal
at day 10.5 in utero.26 Conversely, unlike Necrostatin-1
derivatives such as Necrostatin-1s, Necrostain-1 is a
reactive and to some extent non-specific inhibitor,82,90
which may explain some discrepancies in the activities of
the two molecules.
Necrostatin-1 derivatives: The new Necrostatin-1 analog,
Necrostatin-1 stable (Necrostatin-1s) (7-Cl-O-Nec-1), was
found to be 41 000-fold more selective for RIPK1 than for
any other kinase.91 Moreover, a small group substitution at
the seventh position of the indole of Necrostatin-1 and a
change from thiohydantoin to hydantoin significantly
enhanced its inhibitory activity.82 Necrostatin-1s was
demonstrated to be very effective in reducing brain
injuries6,38
Other RIP-1 inhibitors: Harris et al.92 discovered some
inhibitors for RIPK1 from three different molecule families.
One of these families, furo[2,3-d]pyrimidines, has been
shown to protect rats from hypothermia induced by
TNF-α.92 Weng et al.93 demonstrated that RIPK1 inhibitor
GSK′963, but not inactive enantiomer GSK′962, blocks
Yersinia pestis-induced cell death and caspase-8 activity.
Caspase-8 conditional KO macrophages are protected from
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Y. pestis-induced death in the presence of RIPK1 (GSK’963)
or RIPK3 (GSK’872) kinase inhibitors.93
RIPK3 inhibitor. The ability of RIPK3 deficiency to prevent
disease has heightened interest in the therapeutic potential of
small-molecule inhibitors that target RIPK3 kinase activity.
Mandal et al.94 demonstrated that three selective small-
molecule compounds (GSK′840, GSK′843 and GSK′872) to
inhibit RIPK3-dependent necroptosis. These compounds
interact with RIPK3 to activate caspase-8 (Casp8). RIPK3-
inhibiting compounds blocked TNF-induced necroptosis in a
concentration-dependent manner. In addition, RIPK3 inhibi-
tors prevent death from a broader range of stimuli than RIPK1
inhibitors. Li et al.95 reported that RIPK3 activation following
the induction of necroptosis required the activity of an HSP90
and a CDC37 cochaperone complex. Chemical inhibitors of
HSP90 efficiently block necroptosis by preventing RIPK3
activation.
Potential cytotoxicity of RIPK3 inhibition compounds was
recently observed and revealed by Mandal et al.94 Transmis-
sion electron microscopy confirmed apoptotic cell morphology
associated with RIPK3i cytotoxicity, indicating that RIPK3
inhibition compounds could induce apoptotic cell death.
Inhibitor of downstream signalling components. The
downstream signalling cascade of RIPK1 may provide a
significant array of novel candidate of therapeutic targets.
This area certainly warrants further research.
MLKL inhibitor: The RIP downstream effector, MLKL, has
been identified as another target of antinecroptosis therapy.96
A new compound named necrosulfonamide ((E)-N-(4-(N-(3-
methoxypyrazin-2-yl) sulfamoyl) phenyl)-3-(5-nitrothiophene-
2-yl) acrylamide), referred to as NSA, can effectively block
TNF-induced necroptosis in human cells through interacting
with MLKL.4 NSA could become a new drug for clinical
applications in treating necroptosis related human disease.
Conclusion
Based on effects seen in RIPK3-deficient mice, and
on preclinical investigation of Necrostatin-1, a pathophysiolo-
gical role of necroptosis in numerous diseases may be
concluded.97,98 Although the molecular mechanisms of
necroptosis have not been fully explored, it is clearly possible
that this process is involved in promoting organ injury. Thus,
further understanding of the underlying mechanisms of
necroptosis and its inhibition has important implications for
organ protection and should have a significant impact on the
development of therapeutic intervention of related human
diseases.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. This work was supported by the British Medical Research
Council, The Developmental Pathway Funding Scheme program (project grant
G802392), BJA/RCoA Research Fellowship grant. Work in the Linkermann-lab is
supported by the German Research Foundation, EXC306, Inflammation at Interfaces.
1. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of
necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700–714.
2. Kanduc D, Mittelman A, Serpico R, Sinigaglia E, Sinha AA, Natale C et al. Cell death:
apoptosis versus necrosis (review). Int J Oncol 2002; 21: 165–170.
3. Newton K, Dugger DL, Wickliffe KE, Kapoor N, de Almagro MC, Vucic D et al. Activity of
protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science
2014; 343: 1357–1360.
4. Sun L, Wang H, Wang Z, He S, Chen S, Liao D et al. Mixed lineage kinase domain-like
protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012; 148: 213–227.
5. Luedde M, Lutz M, Carter N, Sosna J, Jacoby C, Vucur M et al. RIP3, a kinase promoting
necroptotic cell death, mediates adverse remodelling after myocardial infarction.
Cardiovasc Res 2014; 103: 206–216.
6. You Z, Savitz SI, Yang J, Degterev A, Yuan J, Cuny GD et al. Necrostatin-1 reduces
histopathology and improves functional outcome after controlled cortical impact in mice.
J Cereb Blood Flow Metab 2008; 28: 1564–1573.
7. Linkermann A, Green DR. Necroptosis. N Engl J Med 2014; 370: 455–465.
8. Pavlosky A, Lau A, Su Y, Lian D, Huang X, Yin Z et al. RIPK3-mediated necroptosis
regulates cardiac allograft rejection. Am J Transplant 2014; 14: 1778–1790.
9. Lau A, Wang S, Jiang J, Haig A, Pavlosky A, Linkermann A et al. RIPK3-mediated
necroptosis promotes donor kidney inflammatory injury and reduces allograft survival. Am
J Transplant 2013; 13: 2805–2818.
10. Declercq W, Vanden Berghe T, Vandenabeele P. RIP kinases at the crossroads of cell
death and survival. Cell 2009; 138: 229–232.
11. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2:
725–734.
12. Vanlangenakker N, Bertrand MJ, Bogaert P, Vandenabeele P, Vanden Berghe T.
TNF-induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex I and
II members. Cell Death Dis 2011; 2: e230.
13. Vanlangenakker N, Vanden Berghe T, Bogaert P, Laukens B, Zobel K, Deshayes K et al.
cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-
dependent reactive oxygen species production. Cell Death Differ 2011; 18: 656–665.
14. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ et al. Identification of a
molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008;
135: 1311–1323.
15. Moquin DM, McQuade T, Chan FK. CYLD deubiquitinates RIP1 in the TNFalpha-induced
necrosome to facilitate kinase activation and programmed necrosis. PLoS One 2013; 8:
e76841.
16. de Almagro MC, Goncharov T, Newton K, Vucic D. Cellular IAP proteins and LUBAC
differentially regulate necrosome-associated RIP1 ubiquitination. Cell Death Dis 2015; 6:
e1800.
17. O'Donnell MA, Perez-Jimenez E, Oberst A, Ng A, Massoumi R, Xavier R et al. Caspase 8
inhibits programmed necrosis by processing CYLD. Nat Cell Biol 2011; 13: 1437–1442.
18. Li J, McQuade T, Siemer AB, Napetschnig J, Moriwaki K, Hsiao YS et al. The RIP1/RIP3
necrosome forms a functional amyloid signaling complex required for programmed
necrosis. Cell 2012; 150: 339–350.
19. Cai Z, Jitkaew S, Zhao J, Chiang HC, Choksi S, Liu J et al. Plasma membrane translocation
of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol 2014; 16:
55–65.
20. Linkermann A, Brasen JH, Darding M, Jin MK, Sanz AB, Heller JO et al. Two independent
pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci
USA 2013; 110: 12024–12029.
21. Morioka S, Broglie P, Omori E, Ikeda Y, Takaesu G, Matsumoto K et al. TAK1 kinase
switches cell fate from apoptosis to necrosis following TNF stimulation. J Cell Biol 2014;
204: 607–623.
22. Lamothe B, Lai Y, Xie M, Schneider MD, Darnay BG. TAK1 is essential for osteoclast
differentiation and is an important modulator of cell death by apoptosis and necroptosis.
Mol Cell Biol 2013; 33: 582–595.
23. Saveljeva S, Mc Laughlin SL, Vandenabeele P, Samali A, Bertrand MJ. Endoplasmic
reticulum stress induces ligand-independent TNFR1-mediated necroptosis in L929 cells.
Cell Death Dis 2015; 6: e1587.
24. Christofferson DE, Yuan J. Necroptosis as an alternative form of programmed cell death.
Curr Opin Cell Biol 2010; 22: 263–268.
25. Dillon CP, Weinlich R, Rodriguez DA, Cripps JG, Quarato G, Gurung P et al. RIPK1
blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell 2014; 157:
1189–1202.
26. Takahashi N, Vereecke L, Bertrand MJ, Duprez L, Berger SB, Divert T et al. RIPK1 ensures
intestinal homeostasis by protecting the epithelium against apoptosis. Nature 2014; 513:
95–99.
27. Kaiser WJ, Daley-Bauer LP, Thapa RJ, Mandal P, Berger SB, Huang C et al. RIP1
suppresses innate immune necrotic as well as apoptotic cell death during mammalian
parturition. Proc Natl Acad Sci USA 2014; 111: 7753–7758.
28. Linkermann A, Brasen JH, Himmerkus N, Liu S, Huber TB, Kunzendorf U et al. Rip1
(receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal
ischemia/reperfusion injury. Kidney Int 2012; 81: 751–761.
29. Rickard JA, O'Donnell JA, Evans JM, Lalaoui N, Poh AR, Rogers T et al. RIPK1 regulates
RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 2014; 157:
1175–1188.
Necroptosis in solid organ injury
H Zhao et al
8
Cell Death and Disease
30. Roderick JE, Hermance N, Zelic M, Simmons MJ, Polykratis A, Pasparakis M et al.
Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and
RIPK3-mediated necroptosis. Proc Natl Acad Sci USA 2014; 111: 14436–14441.
31. Davidovich P, Kearney CJ, Martin SJ. Inflammatory outcomes of apoptosis, necrosis and
necroptosis. Biol Chem 2014; 395: 1163–1171.
32. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature 2015; 517:
311–320.
33. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the
immune arsenal. Nat Rev Immunol 2005; 5: 331–342.
34. Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-
associated molecular patterns and its physiological relevance. Immunity 2013; 38:
209–223.
35. Linkermann A, De Zen F, Weinberg J, Kunzendorf U, Krautwald S. Programmed necrosis in
acute kidney injury. Nephrol Dial Transplant 2012; 27: 3412–3419.
36. Chavez-Valdez R, Martin LJ, Northington FJ. Programmed necrosis: a prominent
mechanism of cell death following neonatal brain injury. Neurol Res Int 2012; 2012: 257563.
37. Northington FJ, Chavez-Valdez R, Graham EM, Razdan S, Gauda EB, Martin LJ.
Necrostatin decreases oxidative damage, inflammation, and injury after neonatal HI.
J Cereb Blood Flow Metab 2011; 31: 178–189.
38. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of
nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol
2005; 1: 112–119.
39. Kooijman E, Nijboer CH, van Velthoven CT, Kavelaars A, Kesecioglu J, Heijnen CJ. The
rodent endovascular puncture model of subarachnoid hemorrhage: mechanisms of brain
damage and therapeutic strategies. J Neuroinflammation 2014; 11: 2.
40. King MD, Whitaker-Lea WA, Campbell JM, Alleyne Jr CH, Dhandapani KM. Necrostatin-1
reduces neurovascular injury after intracerebral hemorrhage. Int J Cell Biol 2014; 2014:
495817.
41. Re DB, Le Verche V, Yu C, Amoroso MW, Politi KA, Phani S et al. Necroptosis drives
motor neuron death in models of both sporadic and familial ALS. Neuron 2014; 81:
1001–1008.
42. Xu X, Chua CC, Kong J, Kostrzewa RM, Kumaraguru U, Hamdy RC et al. Necrostatin-1
protects against glutamate-induced glutathione depletion and caspase-independent cell
death in HT-22 cells. J Neurochem 2007; 103: 2004–2014.
43. Li Y, Yang X, Ma C, Qiao J, Zhang C. Necroptosis contributes to the NMDA-induced
excitotoxicity in rat's cultured cortical neurons. Neurosci Lett 2008; 447: 120–123.
44. Yamanaka K, Saito Y, Yamamori T, Urano Y, Noguchi N. 24(S)-hydroxycholesterol induces
neuronal cell death through necroptosis, a form of programmed necrosis. J Biol Chem
2011; 286: 24666–24673.
45. Kolsch H, Ludwig M, Lutjohann D, Rao ML. Neurotoxicity of 24-hydroxycholesterol, an
important cholesterol elimination product of the brain, may be prevented by vitamin E and
estradiol-17beta. J Neural Transm 2001; 108: 475–488.
46. Hughes TM, Kuller LH, Lopez OL, Becker JT, Evans RW, Sutton-Tyrrell K et al. Markers of
cholesterol metabolism in the brain show stronger associations with cerebrovascular
disease than Alzheimer's disease. J Alzheimers Dis 2012; 30: 53–61.
47. Yamanaka K, Urano Y, Takabe W, Saito Y, Noguchi N. Induction of apoptosis and
necroptosis by 24(S)-hydroxycholesterol is dependent on activity of acyl-CoA:cholesterol
acyltransferase 1. Cell Death Dis 2014; 5: e990.
48. McComb S, Cheung HH, Korneluk RG, Wang S, Krishnan L, Sad S. cIAP1 and cIAP2 limit
macrophage necroptosis by inhibiting Rip1 and Rip3 activation. Cell Death Differ 2012; 19:
1791–1801.
49. Rodrigue-Gervais IG, Labbe K, Dagenais M, Dupaul-Chicoine J, Champagne C, Morizot A
et al. Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue
necrosis during influenza virus infection to promote host survival. Cell Host Microbe 2014;
15: 23–35.
50. Bleriot C, Dupuis T, Jouvion G, Eberl G, Disson O, Lecuit M. Liver-resident macrophage
necroptosis orchestrates type 1 microbicidal inflammation and type-2-mediated tissue
repair during bacterial infection. Immunity 2015; 42: 145–158.
51. Zang D, Shao Y, Li X. Ultrastructural pathology of rat lung injury induced by ischemic acute
kidney injury. Ultrastruct Pathol 2013; 37: 433–439.
52. Zhao H, Ning J, Lemaire A, Koumpa FS, Sun JJ, Fung A et al. Necroptosis and parthanatos
are involved in remote lung injury after receiving ischemic renal allografts in rats. Kidney Int
2014; 87: 738–748.
53. Mizumura K, Cloonan SM, Nakahira K, Bhashyam AR, Cervo M, Kitada T et al. Mitophagy-
dependent necroptosis contributes to the pathogenesis of COPD. J Clin Invest 2014; 124:
3987–4003.
54. Tait SW, Oberst A, Quarato G, Milasta S, Haller M, Wang R et al. Widespread
mitochondrial depletion via mitophagy does not compromise necroptosis. Cell Rep 2013; 5:
878–885.
55. Qing DY, Conegliano D, Shashaty MG, Seo J, Reilly JP, Worthen GS et al. Red blood cells
induce necroptosis of lung endothelial cells and increase susceptibility to lung inflammation.
Am J Respir Crit Care Med 2014; 190: 1243–1254.
56. Xu Y, Ma H, Shao J, Wu J, Zhou L, Zhang Z et al. A Role for Tubular Necroptosis in
Cisplatin-Induced AKI. J Am Soc Nephrol 2015; e-pub ahead of print 18 March 2015.
57. Tristao VR, Goncalves PF, Dalboni MA, Batista MC, Durao Mde S Jr., Monte JC.
Nec-1 protects against nonapoptotic cell death in cisplatin-induced kidney injury. Ren Fail
2012; 34: 373–377.
58. Linkermann A, Skouta R, Himmerkus N, Mulay SR, Dewitz C, De Zen F et al. Synchronized
renal tubular cell death involves ferroptosis. Proc Natl Acad Sci USA 2014; 111:
16836–16841.
59. Linkermann A, Chen G, Dong G, Kunzendorf U, Krautwald S, Dong Z. Regulated cell
death in AKI. J Am Soc Nephrol 2014; 25: 2689–2701.
60. Smith CC, Davidson SM, Lim SY, Simpkin JC, Hothersall JS, Yellon DM. Necrostatin:
a potentially novel cardioprotective agent? Cardiovasc Drugs Ther 2007; 21:
227–233.
61. Koshinuma S, Miyamae M, Kaneda K, Kotani J, Figueredo VM. Combination of necroptosis
and apoptosis inhibition enhances cardioprotection against myocardial ischemia-
reperfusion injury. J Anesth 2014; 28: 235–241.
62. Oerlemans MI, Liu J, Arslan F, den Ouden K, van Middelaar BJ, Doevendans PA et al.
Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after
myocardial ischemia-reperfusion in vivo. Basic Res Cardiol 2012; 107: 270.
63. Lin J, Li H, Yang M, Ren J, Huang Z, Han F et al. A role of RIP3-mediated macrophage
necrosis in atherosclerosis development. Cell Rep 2013; 3: 200–210.
64. Dannappel M, Vlantis K, Kumari S, Polykratis A, Kim C, Wachsmuth L et al. RIPK1
maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 2014; 513:
90–94.
65. Pierdomenico M, Negroni A, Stronati L, Vitali R, Prete E, Bertin J et al. Necroptosis is active
in children with inflammatory bowel disease and contributes to heighten intestinal
inflammation. Am J Gastroenterol 2014; 109: 279–287.
66. Homsi E, Andreazzi DD, Lopes de Faria JB, Janino P. TNF-alpha-mediated
cardio-renal injury after rhabdomyolysis in rats. Am J Physiol Renal Physiol 2014; 308:
F1259–F1267.
67. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;
359: 1541–1549.
68. Gunther C, Martini E, Wittkopf N, Amann K, Weigmann B, Neumann H et al. Caspase-8
regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 2011; 477:
335–339.
69. Roychowdhury S, Chiang DJ, Mandal P, McMullen MR, Liu X, Cohen JI et al. Inhibition of
apoptosis protects mice from ethanol-mediated acceleration of early markers of
CCl4-induced fibrosis but not steatosis or inflammation. Alcohol Clin Exp Res 2012; 36:
1139–1147.
70. Gautheron J, Vucur M, Reisinger F, Cardenas DV, Roderburg C, Koppe C et al. A positive
feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol
Med 2014; 6: 1062–1074.
71. Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in
liver disease: mechanisms and clinical relevance. Gastroenterology 2014; 147:
765–783 e764.
72. Takemoto K, Hatano E, Iwaisako K, Takeiri M, Noma N, Ohmae S et al. Necrostatin-1
protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-
induced acute liver failure. FEBS Open Bio 2014; 4: 777–787.
73. Brune K, Renner B, Tiegs G. Acetaminophen/paracetamol: a history of errors, failures and
false decisions. Eur J Pain 2014; 19: 953–965.
74. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils
and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33.
Blood 2009; 113: 1526–1534.
75. Lim EJ, El Khobar K, Chin R, Earnest-Silveira L, Angus PW, Bock CT et al. Hepatitis C
virus-induced hepatocyte cell death and protection by inhibition of apoptosis. J Gen Virol
2014; 95(Pt 10): 2204–2215.
76. Bao C, Shao Y, Li X. Hepatocyte necroptosis induced by ischemic acute kidney injury
in rats. Ultrastruct Pathol 2014; 38: 217–223.
77. He S, Wang L, Miao L, Wang T, Du F, Zhao L et al. Receptor interacting protein kinase-3
determines cellular necrotic response to TNF-alpha. Cell 2009; 137: 1100–1111.
78. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC et al. RIP3, an energy metabolism
regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009;
325: 332–336.
79. Linkermann A, Brasen JH, De Zen F, Weinlich R, Schwendener RA, Green DR et al.
Dichotomy between RIP1- and RIP3-mediated necroptosis in tumor necrosis factor-alpha-
induced shock. Mol Med 2012; 18: 577–586.
80. Wu J, Huang Z, Ren J, Zhang Z, He P, Li Y et al. Mlkl knockout mice demonstrate the
indispensable role of Mlkl in necroptosis. Cell Res 2013; 23: 994–1006.
81. Moriwaki K, Balaji S, McQuade T, Malhotra N, Kang J, Chan FK. The necroptosis adaptor
RIPK3 promotes injury-induced cytokine expression and tissue repair. Immunity 2014; 41:
567–578.
82. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X et al. Identification
of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4:
313–321.
83. Zhou Z, Han V, Han J. New components of the necroptotic pathway. Protein Cell 2012; 3:
811–817.
84. Trichonas G, Murakami Y, Thanos A, Morizane Y, Kayama M, Debouck CM et al. Receptor
interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and
compensate for inhibition of apoptosis. Proc Natl Acad Sci USA 2010; 107: 21695–21700.
85. Bertrand MJ, Vandenabeele P. RIP1's function in NF-kappaB activation: from master actor
to onlooker. Cell Death Differ 2010; 17: 379–380.
Necroptosis in solid organ injury
H Zhao et al
9
Cell Death and Disease
86. Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB et al.
Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in
experimental disease models. Cell Death Dis 2012; 3: e437.
87. Ofengeim D, Yuan J. Regulation of RIP1 kinase signalling at the crossroads of inflammation
and cell death. Nat Rev Mol Cell Biol 2013; 14: 727–736.
88. Xie T, Peng W, Liu Y, Yan C, Maki J, Degterev A et al. Structural basis of RIP1 inhibition by
necrostatins. Structure 2013; 21: 493–499.
89. Kaiser WJ, Upton JW, Mocarski ES. Receptor-interacting protein homotypic interaction
motif-dependent control of NF-kappa B activation via the DNA-dependent activator of IFN
regulatory factors. J Immunol 2008; 181: 6427–6434.
90. Degterev A, Maki JL, Yuan J. Activity and specificity of necrostatin-1, small-molecule
inhibitor of RIP1 kinase. Cell Death Differ 2013; 20: 366.
91. Christofferson DE, Li Y, Hitomi J, Zhou W, Upperman C, Zhu H et al. A novel role for RIP1
kinase in mediating TNFalpha production. Cell Death Dis 2012; 3: e320.
92. Harris PA, Bandyopadhyay D, Berger SB, Campobasso N, Capriotti CA, Cox JA et al.
Discovery of small molecule RIP1 kinase inhibitors for the treatment of pathologies
associated with necroptosis. ACS Med Chem Lett 2013; 4: 1238–1243.
93. Weng D, Marty-Roix R, Ganesan S, Proulx MK, Vladimer GI, Kaiser WJ et al. Caspase-8
and RIP kinases regulate bacteria-induced innate immune responses and cell death. Proc
Natl Acad Sci USA 2014; 111: 7391–7396.
94. Mandal P, Berger SB, Pillay S, Moriwaki K, Huang C, Guo H et al. RIP3 induces apoptosis
independent of pronecrotic kinase activity. Mol Cell 2014; 56: 481–495.
95. Li D, Xu T, Cao Y, Wang H, Li L, Chen S et al. A cytosolic heat shock protein 90 and
cochaperone CDC37 complex is required for RIP3 activation during necroptosis. Proc Natl
Acad Sci USA 2015; 112: 5017–5022.
96. Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang JG, Alvarez-Diaz S et al. The
pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity
2013; 39: 443–453.
97. Linkermann A, Stockwell BR, Krautwald S, Anders HJ. Regulated cell death and
inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol 2014; 14:
759–767.
98. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P.
Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev
Mol Cell Biol 2014; 15: 135–147.
99. Vanden Berghe T, Vanlangenakker N, Parthoens E, Deckers W, Devos M, Festjens N et al.
Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration
features. Cell Death Differ 2010; 17: 922–930.
100. Kearney CJ, Cullen SP, Tynan GA, Henry CM, Clancy D, Lavelle EC et al. Necroptosis
suppresses inflammation via termination of TNF- or LPS-induced cytokine and chemokine
production. Cell Death Differ 2015; 22: 1313–1327.
101. Zhao H, Watts HR, Chong M, Huang H, Tralau-Stewart C, Maxwell PH et al. Xenon
treatment protects against cold ischemia associated delayed graft function and prolongs
graft survival in rats. Am J Transplant 2013; 13: 2006–2018.
102. Asavarut P, Zhao H, Gu J, Ma D. The role of HMGB1 in inflammation-mediated
organ injury. Acta Anaesthesiol Taiwan 2013; 51: 28–33.
103. Allam R, Scherbaum CR, Darisipudi MN, Mulay SR, Hagele H, Lichtnekert J et al. Histones
from dying renal cells aggravate kidney injury via TLR2 and TLR4. J Am Soc Nephrol 2012;
23: 1375–1388.
104. Abrams ST, Zhang N, Manson J, Liu T, Dart C, Baluwa F et al. Circulating histones are
mediators of trauma-associated lung injury. Am J Respir Crit Care Med 2013; 187:
160–169.
105. Maitre B, Magnenat S, Heim V, Ravanat C, Evans RJ, de la Salle H et al. The P2X1
receptor is required for neutrophil extravasation during lipopolysaccharide-induced lethal
endotoxemia in mice. J Immunol 2015; 194: 739–749.
106. Thaxton JE, Liu B, Zheng P, Liu Y, Li Z. Deletion of CD24 impairs development of heat
shock protein gp96-driven autoimmune disease through expansion of myeloid-derived
suppressor cells. J Immunol 2014; 192: 5679–5686.
107. Zhao H, Perez JS, Lu K, George AJ, Ma D. Role of Toll-like receptor-4 in
renal graft ischemia-reperfusion injury. Am J Physiol Renal Physiol 2014; 306:
F801–F811.
108. Kuck JL, Obiako BO, Gorodnya OM, Pastukh VM, Kua J, Simmons JD et al. Mitochondrial
DNA damage-associated molecular patterns mediate a feed-forward cycle of bacteria-
induced vascular injury in perfused rat lungs. Am J Physiol Lung Cell Mol Physiol 2015; 308:
L1078–L1085.
109. Rosin DL, Okusa MD. Dangers within: DAMP responses to damage and cell death in kidney
disease. J Am Soc Nephrol 2011; 22: 416–425.
110. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM. Interleukin-33 – cytokine of
dual function or novel alarmin? Trends Immunol 2009; 30: 227–233.
111. Dear JW, Simpson KJ, Nicolai MP, Catterson JH, Street J, Huizinga T et al. Cyclophilin A is
a damage-associated molecular pattern molecule that mediates acetaminophen-induced
liver injury. J Immunol 2011; 187: 3347–3352.
112. Christofferson DE, Yuan J. Cyclophilin A release as a biomarker of necrotic cell death. Cell
Death Differ 2010; 17: 1942–1943.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material in this article are
included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the
Creative Commons license, users will need to obtain permission from
the license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/
Necroptosis in solid organ injury
H Zhao et al
10
Cell Death and Disease
